State Street Corp increased its holdings in shares of Clover Health Investments, Corp. (NASDAQ:CLOV – Free Report) by 65.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,189,380 shares of the company’s stock after purchasing an additional 862,621 shares during the period. State Street Corp owned 0.44% of Clover Health Investments worth $6,174,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Concurrent Investment Advisors LLC purchased a new stake in Clover Health Investments during the third quarter worth $28,000. Sigma Planning Corp purchased a new stake in shares of Clover Health Investments during the 3rd quarter worth $29,000. Parallax Volatility Advisers L.P. purchased a new stake in shares of Clover Health Investments during the 3rd quarter worth $38,000. Vanguard Personalized Indexing Management LLC boosted its position in Clover Health Investments by 54.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 34,372 shares of the company’s stock valued at $42,000 after purchasing an additional 12,104 shares in the last quarter. Finally, Realta Investment Advisors purchased a new position in Clover Health Investments in the third quarter valued at about $44,000. 19.77% of the stock is owned by hedge funds and other institutional investors.
Clover Health Investments Trading Down 1.5 %
Shares of Clover Health Investments stock opened at $3.26 on Friday. Clover Health Investments, Corp. has a 12-month low of $0.61 and a 12-month high of $4.71. The firm’s 50 day simple moving average is $3.49 and its two-hundred day simple moving average is $2.76. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -16.30 and a beta of 1.94.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on the stock. Craig Hallum initiated coverage on shares of Clover Health Investments in a report on Tuesday, December 17th. They issued a “buy” rating and a $6.00 price target on the stock. UBS Group initiated coverage on shares of Clover Health Investments in a research note on Monday, October 7th. They issued a “neutral” rating and a $4.00 target price for the company.
Get Our Latest Stock Analysis on Clover Health Investments
About Clover Health Investments
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.
See Also
- Five stocks we like better than Clover Health Investments
- How to Invest in the Best Canadian Stocks
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- EV Stocks and How to Profit from Them
- Top 3 ETFs to Hedge Against Inflation in 2025
- Why Invest in 5G? How to Invest in 5G Stocks
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.